Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions: Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions: Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT); Radiation · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions: One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils; Device
Lead sponsor: Desin LLC; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Violence
Interventions: Second Step + R-CITY, Second Step Only; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Cancer
Interventions: OST31-164; Drug
Lead sponsor: Emerald Clinical Inc.; Industry
Eligibility: 12 Years to 39 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • San Diego, California + 18 more

Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
Interventions: Ion Endoluminal System; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Orlando, Florida • Elk Grove Village, Illinois • Quincy, Illinois + 13 more

Conditions: Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions: Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Critical Illness
Interventions: PICU Up!; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 24 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small-Cell Lung Cancer
Interventions: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
Interventions: Placebo Oral Capsule, NYX-458; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 15
States / cities: Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more

Conditions: Geographic Atrophy
Interventions: Placebo-matching BI 1584862, BI 1584862; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Aging
Interventions: Pecan, Pretzel; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 29
States / cities: Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more

Conditions: COVID-19
Interventions: Citicoline, Saline/Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asymptomatic
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration; Diagnostic Test · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 67
States / cities: Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more

Conditions: Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
Interventions: Biospecimen Collection-Blood, Biospecimen Collection-Stool; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy
Interventions: Bifidobacterium; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Microbiome, Human, Gastrointestinal Tract
Interventions: Food provided from a commercial meal service provider for a week; Other
Lead sponsor: University of Nebraska Lincoln; Other
Eligibility: 19 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multiple Myeloma
Interventions: Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 30
States / cities: Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more

Conditions: Prostate Cancer
Interventions: Darolutamide(Nubeqa, BAY1841788); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 24
States / cities: Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more

Conditions: Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
Interventions: Carbon Dioxide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Romosozumab Use to Build Skeletal Integrity

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Obi Medical Robot: Evaluating Effectiveness Related to Usability

The R-CITY Project: A Collaborative Intervention With Teachers and Youth

Effects of Psilocybin in Obsessive Compulsive Disorder

Osteosarcoma Maintenance Therapy With OST31-164

Real World Registry for Use of the Ion Endoluminal System

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children

Study of AZD2811 + Durvalumab in ES-SCLC

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Effect of Snacks on Aging

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

Infant Microbiota and Probiotic Intake Study

Diet and Microbiome Longitudinal Monitoring With Food Intervention

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

Metabolic and Hemodynamic Reserve in Pediatric SCA